Načítá se...

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

BACKGROUND: Lipoprotein apheresis (LA) is considered as an add-on therapy for patients with familial hypercholesterolemia (FH). We aimed to analyze the data collected in the last 15 years from FH patients treated with LA, to elucidate the benefit of this procedure with respect to plasma lipids, biom...

Celý popis

Uloženo v:

Podrobná bibliografie
Vydáno v:	Orphanet J Rare Dis
Hlavní autoři:	Víšek, J., Bláha, M., Bláha, V., Lášticová, M., Lánska, M., Andrýs, C., Tebbens, J. Duintjer, Igreja e Sá, Ivone Cristina, Tripská, K., Vicen, M., Najmanová, I., Nachtigal, P.
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	BioMed Central 2021
Témata:	Research
On-line přístup:	https://ncbi.nlm.nih.gov/pmc/articles/PMC7913462/ https://ncbi.nlm.nih.gov/pubmed/33640001 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s13023-021-01749-w
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo otaguje tento záznam!

Monitoring of up to 15 years effects of lipoprotein apheresis on lipids, biomarkers of inflammation, and soluble endoglin in familial hypercholesterolemia patients

Podobné jednotky